The decision to move Reata Pharmaceuticals Inc.'s bardoxolone into sicker kidney disease patients in Phase III may have been intended to get to results faster. Instead, the move may have amplified toxicity signals seen in Phase II patients with less advanced disease.

On Oct. 18, Reata said it would stop all studies in chronic kidney disease (CKD), including the Phase III BEACON trial in Type II diabetics with CKD, because of an excess of serious adverse events and mortality in the treatment group.